Keywords
Last Name

Gene Garrard Olinger, PhD

TitleAdjunct Associate Professor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionInfectious Diseases
Address620 Albany St
Boston MA 02118
Phone(617) 638-7536
ORCID ORCID Icon0000-0001-7338-0292
Other Positions
TitleAssociate Director for Maximum Containment Training, NEIDL
InstitutionBoston University School of Medicine
DepartmentNational Emerging Infectious Disease Lab

 Research Expertise & Professional Interests
Gene Garrard Olinger, Jr. received his Ph.D. from Rush University Medical Center in Chicago, IL in 2001. Currently, Dr. Olinger is the principal advisor science for MRI Global Inc.

Dr. Olinger holds a Masters in Business Administration from Mount Saint Mary’s University in Emmittsburg, MD, has completed executive training at Massachusetts Institute of Technology, Boston, MA, and completed Department of Defense Acquisition and Executive Leadership training. He is the recipient of the Achievement Medal for Civilian Service Medals in 2005 and 2010, Commander’s Award for Civilian Service in 2013, and the NIH Director Award in 2015 for his efforts assisting with the Ebola outbreak in Western Africa. Dr. Olinger is active in multiple STEM programs and mentors high school, undergraduate graduate students and post-doctoral fellows.

 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, Michelotti J, Dewey WH, DeWald LE, Bennett RS, Morris PJ, Guha R, Klumpp-Thomas C, McKnight C, Chen YC, Xu X, Wang A, Hughes E, Martin S, Thomas C, Jahrling PB, Hensley LE, Olinger GG, White JM. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. PLoS Negl Trop Dis. 2017 Apr; 11(4):e0005540. PMID: 28403145.
    View in: PubMed
  2. Dyall J, Hart BJ, Postnikova E, Cong Y, Zhou H, Gerhardt DM, Freeburger D, Michelotti J, Honko AN, DeWald LE, Bennett RS, Olinger GG, Jahrling PB, Hensley LE. Interferon-beta and Interferon-gamma Are Weak Inhibitors of Ebola Virus in Cell-based Assays. J Infect Dis. 2017 Mar 22. PMID: 28368541.
    View in: PubMed
  3. Cong Y, Dyall J, Hart BJ, DeWald LE, Johnson JC, Postnikova E, Zhou H, Gross R, Rojas O, Alexander I, Josleyn N, Zhang T, Michelotti J, Janosko K, Glass PJ, Flint M, McMullan LK, Spiropoulou CF, Mierzwa T, Guha R, Shinn P, Michael S, Klumpp-Thomas C, McKnight C, Thomas C, Eakin AE, O'Loughlin KG, Green CE, Catz P, Mirsalis JC, Honko AN, Olinger GG, Bennett RS, Holbrook MR, Hensley LE, Jahrling PB. Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus. PLoS One. 2016; 11(11):e0166318. PMID: 27902714.
    View in: PubMed
  4. Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao JA, Matsushita H, Liu Y, Postnikova EN, Ork BL, Glenn G, Flyer D, Defang G, Raviprakash K, Kochel T, Wang J, Nie W, Smith G, Hensley LE, Olinger GG, Kuhn JH, Holbrook MR, Johnson RF, Perlman S, Sullivan E, Frieman MB. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med. 2016 Feb 17; 8(326):326ra21. PMID: 26888429.
    View in: PubMed
  5. Johnson RF, Bagci U, Keith L, Tang X, Mollura DJ, Zeitlin L, Qin J, Huzella L, Bartos CJ, Bohorova N, Bohorov O, Goodman C, Kim do H, Paulty MH, Velasco J, Whaley KJ, Johnson JC, Pettitt J, Ork BL, Solomon J, Oberlander N, Zhu Q, Sun J, Holbrook MR, Olinger GG, Baric RS, Hensley LE, Jahrling PB, Marasco WA. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology. 2016 Mar; 490:49-58. PMID: 26828465.
    View in: PubMed
  6. Zeitlin L, Whaley KJ, Olinger GG, Jacobs M, Gopal R, Qiu X, Kobinger GP. Antibody therapeutics for Ebola virus disease. Curr Opin Virol. 2016 Apr; 17:45-9. PMID: 26826442.
    View in: PubMed
  7. McMullan LK, Flint M, Dyall J, Albariño C, Olinger GG, Foster S, Sethna P, Hensley LE, Nichol ST, Lanier ER, Spiropoulou CF. The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. Antiviral Res. 2016 Jan; 125:71-8. PMID: 26526586.
    View in: PubMed
  8. Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim do H, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO. Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS Pathog. 2015 Oct; 11(10):e1005212. PMID: 26452225.
    View in: PubMed
  9. Kugelman JR, Kugelman-Tonos J, Ladner JT, Pettit J, Keeton CM, Nagle ER, Garcia KY, Froude JW, Kuehne AI, Kuhn JH, Bavari S, Zeitlin L, Dye JM, Olinger GG, Sanchez-Lockhart M, Palacios GF. Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. Cell Rep. 2015 Sep 29; 12(12):2111-20. PMID: 26365189.
    View in: PubMed
  10. Racsa LD, Kraft CS, Olinger GG, Hensley LE. Viral Hemorrhagic Fever Diagnostics. Clin Infect Dis. 2016 Jan 15; 62(2):214-9. PMID: 26354968.
    View in: PubMed
  11. Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015; 6:7712. PMID: 26218507.
    View in: PubMed
  12. Cheng H, Lear-Rooney CM, Johansen L, Varhegyi E, Chen ZW, Olinger GG, Rong L. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. J Virol. 2015 Oct; 89(19):9932-8. PMID: 26202243.
    View in: PubMed
  13. Meyer M, Garron T, Lubaki NM, Mire CE, Fenton KA, Klages C, Olinger GG, Geisbert TW, Collins PL, Bukreyev A. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest. 2015 Aug 3; 125(8):3241-55. PMID: 26168222.
    View in: PubMed
  14. Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim do H, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Berry J, Saphire EO. Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS Pathog. 2015 Jun; 11(6):e1005016. PMID: 26115029.
    View in: PubMed
  15. Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, Nelson E, Delos SE, Simmons JA, Grenier JM, Pierce LT, Pajouhesh H, Lehár J, Hensley LE, Glass PJ, White JM, Olinger GG. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci Transl Med. 2015 Jun 3; 7(290):290ra89. PMID: 26041706.
    View in: PubMed
  16. Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, Eller MA, Eller LA, Michael NL, Honko AN, Olinger GG, Schoepp RJ, Hepburn MJ, Hensley LE, Robb ML. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis. 2015 Aug; 15(8):905-12. PMID: 25910637.
    View in: PubMed
  17. O'Hearn A, Wang M, Cheng H, Lear-Rooney CM, Koning K, Rumschlag-Booms E, Varhegyi E, Olinger G, Rong L. Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry. J Virol. 2015 May; 89(10):5441-9. PMID: 25741008.
    View in: PubMed
  18. Hensley LE, Dyall J, Olinger GG, Jahrling PB. Lack of effect of lamivudine on Ebola virus replication. Emerg Infect Dis. 2015 Mar; 21(3):550-2. PMID: 25695153.
    View in: PubMed
  19. Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH, Olinger GG, Hensley LE, Jahrling PB. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother. 2015 Feb; 59(2):1088-99. PMID: 25487801.
    View in: PubMed
  20. Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A. 2014 Dec 2; 111(48):17182-7. PMID: 25404321.
    View in: PubMed
  21. Garrison AR, Giomarelli BG, Lear-Rooney CM, Saucedo CJ, Yellayi S, Krumpe LR, Rose M, Paragas J, Bray M, Olinger GG, McMahon JB, Huggins J, O'Keefe BR. The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Antiviral Res. 2014 Dec; 112:1-7. PMID: 25265598.
    View in: PubMed
  22. Kuhn JH, Andersen KG, Bào Y, Bavari S, Becker S, Bennett RS, Bergman NH, Blinkova O, Bradfute S, Brister JR, Bukreyev A, Chandran K, Chepurnov AA, Davey RA, Dietzgen RG, Doggett NA, Dolnik O, Dye JM, Enterlein S, Fenimore PW, Formenty P, Freiberg AN, Garry RF, Garza NL, Gire SK, Gonzalez JP, Griffiths A, Happi CT, Hensley LE, Herbert AS, Hevey MC, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson JC, Johnson KM, Kindrachuk J, Klenk HD, Kobinger G, Kochel TJ, Lackemeyer MG, Lackner DF, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Omilabu SA, Palacios G, Panchal RG, Park DJ, Patterson JL, Paweska JT, Peters CJ, Pettitt J, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Sabeti PC, Sealfon R, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST. Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names. Viruses. 2014 Sep; 6(9):3663-82. PMID: 25256396.
    View in: PubMed
  23. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014 Oct 2; 514(7520):47-53. PMID: 25171469.
    View in: PubMed
  24. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG, Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ, Hensley LE, Frieman MB. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug; 58(8):4885-93. PMID: 24841273.
    View in: PubMed
  25. Johnson JC, Martinez O, Honko AN, Hensley LE, Olinger GG, Basler CF. Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res. 2014 Jul; 107:102-9. PMID: 24815087.
    View in: PubMed
  26. Wong G, Qiu X, Olinger GG, Kobinger GP. Post-exposure therapy of filovirus infections. Trends Microbiol. 2014 Aug; 22(8):456-63. PMID: 24794572.
    View in: PubMed
  27. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG, Frieman MB, Holbrook MR, Jahrling PB, Hensley L. Interferon-ß and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014 Mar; 95(Pt 3):571-7. PMID: 24323636.
    View in: PubMed
  28. Kuhn JH, Bào Y, Bavari S, Becker S, Bradfute S, Brauburger K, Rodney Brister J, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST. Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol. 2014 May; 159(5):1229-37. PMID: 24190508.
    View in: PubMed
  29. Pettitt J, Zeitlin L, Kim do H, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly MH, Whaley KJ, Ingram MF, Zovanyi A, Heinrich M, Piper A, Zelko J, Olinger GG. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013 Aug 21; 5(199):199ra113. PMID: 23966302.
    View in: PubMed
  30. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013 Jun 19; 5(190):190ra79. PMID: 23785035.
    View in: PubMed
  31. Smither SJ, Lear-Rooney C, Biggins J, Pettitt J, Lever MS, Olinger GG. Comparison of the plaque assay and 50% tissue culture infectious dose assay as methods for measuring filovirus infectivity. J Virol Methods. 2013 Nov; 193(2):565-71. PMID: 23748121.
    View in: PubMed
  32. Reed C, Lin K, Wilhelmsen C, Friedrich B, Nalca A, Keeney A, Donnelly G, Shamblin J, Hensley LE, Olinger G, Smith DR. Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development. PLoS Negl Trop Dis. 2013; 7(4):e2156. PMID: 23593523.
    View in: PubMed
  33. Brudner M, Karpel M, Lear C, Chen L, Yantosca LM, Scully C, Sarraju A, Sokolovska A, Zariffard MR, Eisen DP, Mungall BA, Kotton DN, Omari A, Huang IC, Farzan M, Takahashi K, Stuart L, Stahl GL, Ezekowitz AB, Spear GT, Olinger GG, Schmidt EV, Michelow IC. Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. PLoS One. 2013; 8(4):e60838. PMID: 23573288.
    View in: PubMed
  34. Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, Johansen LM, White JM. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One. 2013; 8(2):e56265. PMID: 23441171.
    View in: PubMed
  35. Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol. 2013 May; 87(9):4952-64. PMID: 23408633.
    View in: PubMed
  36. Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Lofts LL, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST. Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol. 2013 Jun; 158(6):1425-32. PMID: 23358612.
    View in: PubMed
  37. Martinez O, Johnson JC, Honko A, Yen B, Shabman RS, Hensley LE, Olinger GG, Basler CF. Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol. 2013 Apr; 87(7):3801-14. PMID: 23345511.
    View in: PubMed
  38. Twenhafel NA, Mattix ME, Johnson JC, Robinson CG, Pratt WD, Cashman KA, Wahl-Jensen V, Terry C, Olinger GG, Hensley LE, Honko AN. Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques. Vet Pathol. 2013 May; 50(3):514-29. PMID: 23262834.
    View in: PubMed
  39. Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A, Yen JY, Geisbert J, Paragas J, Fritz E, Olinger G, Young HA, Rubins KH, Karp CL. Interferon-ß therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis. 2013 Jul 15; 208(2):310-8. PMID: 23255566.
    View in: PubMed
  40. Shurtleff AC, Biggins JE, Keeney AE, Zumbrun EE, Bloomfield HA, Kuehne A, Audet JL, Alfson KJ, Griffiths A, Olinger GG, Bavari S. Standardization of the filovirus plaque assay for use in preclinical studies. Viruses. 2012 Dec; 4(12):3511-30. PMID: 23223188.
    View in: PubMed
  41. Olinger GG, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A. 2012 Oct 30; 109(44):18030-5. PMID: 23071322.
    View in: PubMed
  42. Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Hensley LE, Honko AN, Jahrling PB, Johnson KM, Kobinger G, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Saphire EO, Smither SJ, Swanepoel R, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Weidmann M, Nichol ST. Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol. 2013 Jan; 158(1):301-11. PMID: 23001720.
    View in: PubMed
  43. Friedrich BM, Trefry JC, Biggins JE, Hensley LE, Honko AN, Smith DR, Olinger GG. Potential vaccines and post-exposure treatments for filovirus infections. Viruses. 2012 Sep; 4(9):1619-50. PMID: 23170176.
    View in: PubMed
  44. Warfield KL, Olinger GG. Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. J Biomed Biotechnol. 2011; 2011:984241. PMID: 22253531.
    View in: PubMed
  45. Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, Pauly M, Hiatt A, Ngo L, Steinkellner H, Whaley KJ, Olinger GG. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):20690-4. PMID: 22143789.
    View in: PubMed
  46. Kortepeter MG, Lawler JV, Honko A, Bray M, Johnson JC, Purcell BK, Olinger GG, Rivard R, Hepburn MJ, Hensley LE. Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J Infect Dis. 2011 Nov; 204 Suppl 3:S1000-10. PMID: 21987736.
    View in: PubMed
  47. Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, Reimann KA, Bao S, Rao S, Roederer M, Jahrling PB, Koup RA, Nabel GJ. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011 Sep; 17(9):1128-31. PMID: 21857654.
    View in: PubMed
  48. Michelow IC, Lear C, Scully C, Prugar LI, Longley CB, Yantosca LM, Ji X, Karpel M, Brudner M, Takahashi K, Spear GT, Ezekowitz RA, Schmidt EV, Olinger GG. High-dose mannose-binding lectin therapy for Ebola virus infection. J Infect Dis. 2011 Jan 15; 203(2):175-9. PMID: 21288816.
    View in: PubMed
  49. Michelow IC, Dong M, Mungall BA, Yantosca LM, Lear C, Ji X, Karpel M, Rootes CL, Brudner M, Houen G, Eisen DP, Kinane TB, Takahashi K, Stahl GL, Olinger GG, Spear GT, Ezekowitz RA, Schmidt EV. A novel L-ficolin/mannose-binding lectin chimeric molecule with enhanced activity against Ebola virus. J Biol Chem. 2010 Aug 6; 285(32):24729-39. PMID: 20516066.
    View in: PubMed
  50. Smith DR, McCarthy S, Chrovian A, Olinger G, Stossel A, Geisbert TW, Hensley LE, Connor JH. Inhibition of heat-shock protein 90 reduces Ebola virus replication. Antiviral Res. 2010 Aug; 87(2):187-94. PMID: 20452380.
    View in: PubMed
  51. Olinger GG. Targeting biodefense markets. Hum Vaccin. 2009 Oct; 5(10):660-5. PMID: 19855169.
    View in: PubMed
  52. Martinez O, Johnson J, Manicassamy B, Rong L, Olinger GG, Hensley LE, Basler CF. Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol. 2010 Feb; 12(2):148-57. PMID: 19775255.
    View in: PubMed
  53. Kalina WV, Warfield KL, Olinger GG, Bavari S. Discovery of common marburgvirus protective epitopes in a BALB/c mouse model. Virol J. 2009; 6:132. PMID: 19712478.
    View in: PubMed
  54. Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, Luo G, Nelson EA, Li L, Huang Z, Murray M, Ellis WY, Hensley L, Christopher-Hennings J, Olinger GG, Goldblatt M. FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Am J Transl Res. 2009; 1(1):87-98. PMID: 19966942.
    View in: PubMed
  55. Anzinger JJ, Olinger GG, Spear GT. Donor variability in HIV binding to peripheral blood mononuclear cells. Virol J. 2008; 5:95. PMID: 18706090.
    View in: PubMed
  56. Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D, Gillette WK, Hopkins RF, Costantino J, Panchal RG, Hartley JL, Aman MJ, Bavari S. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis. 2007 Nov 15; 196 Suppl 2:S421-9. PMID: 17940979.
    View in: PubMed
  57. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Viard M, Aitichou M, Chi X, Ibrahim S, Blumenthal R, Raviv Y, Bavari S, Aman MJ. Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J Infect Dis. 2007 Nov 15; 196 Suppl 2:S276-83. PMID: 17940961.
    View in: PubMed
  58. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis. 2007 Nov 15; 196 Suppl 2:S430-7. PMID: 17940980.
    View in: PubMed
  59. Warfield KL, Alves DA, Bradfute SB, Reed DK, VanTongeren S, Kalina WV, Olinger GG, Bavari S. Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J. 2007; 4:108. PMID: 17961252.
    View in: PubMed
  60. Mohamadzadeh M, Coberley SS, Olinger GG, Kalina WV, Ruthel G, Fuller CL, Swenson DL, Pratt WD, Kuhns DB, Schmaljohn AL. Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by marburg and ebola viruses. J Virol. 2006 Jul; 80(14):7235-44. PMID: 16809329.
    View in: PubMed
  61. Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, Stein DA, Aman MJ, Iversen PL, Bavari S. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2006 Jan; 2(1):e1. PMID: 16415982.
    View in: PubMed
  62. Mohamadzadeh M, Chen L, Olinger GG, Pratt WD, Schmaljohn AL. Filoviruses and the balance of innate, adaptive, and inflammatory responses. Viral Immunol. 2006; 19(4):602-12. PMID: 17201655.
    View in: PubMed
  63. Olinger GG, Bailey MA, Dye JM, Bakken R, Kuehne A, Kondig J, Wilson J, Hogan RJ, Hart MK. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol. 2005 Nov; 79(22):14189-96. PMID: 16254354.
    View in: PubMed
  64. Ji X, Olinger GG, Aris S, Chen Y, Gewurz H, Spear GT. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol. 2005 Sep; 86(Pt 9):2535-42. PMID: 16099912.
    View in: PubMed
  65. Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol. 2005 Jul 15; 175(2):1184-91. PMID: 16002721.
    View in: PubMed
  66. Olinger GG, Saifuddin M, Hart ML, Spear GT. Cellular factors influence the binding of HIV type 1 to cells. AIDS Res Hum Retroviruses. 2002 Mar 1; 18(4):259-67. PMID: 11860673.
    View in: PubMed
  67. Spear GT, Olinger GG, Saifuddin M, Gebel HM. Human antibodies to major histocompatibility complex alloantigens mediate lysis and neutralization of HIV-1 primary isolate virions in the presence of complement. J Acquir Immune Defic Syndr. 2001 Feb 1; 26(2):103-10. PMID: 11242176.
    View in: PubMed
  68. Spear GT, Hart M, Olinger GG, Hashemi FB, Saifuddin M. The role of the complement system in virus infections. Curr Top Microbiol Immunol. 2001; 260:229-45. PMID: 11443876.
    View in: PubMed
  69. Olinger GG, Saifuddin M, Spear GT. CD4-Negative cells bind human immunodeficiency virus type 1 and efficiently transfer virus to T cells. J Virol. 2000 Sep; 74(18):8550-7. PMID: 10954556.
    View in: PubMed
  70. Spear GT, Olinger G, Sullivan BL, Landay AL, Kessler H, Connick E, Kuritzkes D, St Clair M, Spritzler J, Wu H, Lederman MM. Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons. AIDS Res Hum Retroviruses. 1999 Dec 10; 15(18):1713-5. PMID: 10606095.
    View in: PubMed
  71. Olinger GG, Hashemi FB, Sha BE, Spear GT. Association of indicators of bacterial vaginosis with a female genital tract factor that induces expression of HIV-1. AIDS. 1999 Oct 1; 13(14):1905-12. PMID: 10513649.
    View in: PubMed
  72. Al-Harthi L, Roebuck KA, Olinger GG, Landay A, Sha BE, Hashemi FB, Spear GT. Bacterial vaginosis-associated microflora isolated from the female genital tract activates HIV-1 expression. J Acquir Immune Defic Syndr. 1999 Jul 1; 21(3):194-202. PMID: 10421242.
    View in: PubMed
Gene's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department